Linda Tempelman
Chief Executive Officer at Persista Bio.
Earliest Form D on file: Apr 2026
Filed Apr 29, 2026
Persista Bio
Implantable cell therapy for Type 1 diabetes
Biotech, City of Lewes DE
Signed as Chief Executive Officer
Chief Executive Officer at Persista Bio.
Earliest Form D on file: Apr 2026
Implantable cell therapy for Type 1 diabetes
Biotech, City of Lewes DE
Signed as Chief Executive Officer